Shattuck Labs (STTK) investor relations material

Strategic focus and mission

• Dedicated to developing novel biologics for inflammatory and immune-mediated diseases, emphasizing scientific excellence and resource stewardship.

• Vision centers on creating innovative therapeutics by challenging conventional approaches.

Pipeline and lead programs

• Lead asset SL-325 is a potentially first-in-class DR3 blocking antibody for inflammatory bowel disease (IBD), with Phase 1 enrollment nearly complete and Phase 2 planned for Crohn's disease.

• SL-425, a half-life extended DR3 antibody, and bispecific antibodies targeting DR3 and other IBD targets are in preclinical development.

• Blocking DR3 may offer more potent and durable inhibition of the TL1A/DR3 axis than TL1A blockade, with lower immunogenicity.

Scientific rationale and differentiation

• DR3 is constitutively expressed in both inflamed and non-inflamed GI tissue, while TL1A is transiently expressed, supporting DR3 as a superior therapeutic target.

• Preclinical and transcriptomic data confirm higher and more consistent DR3 expression in IBD patients compared to TL1A.

• SL-325 demonstrates picomolar binding affinity to DR3, does not bind the decoy receptor DcR3, and blocks both monomeric and trimeric TL1A.